These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9708428)

  • 1. Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team.
    Gill MJ
    AIDS; 1998 Jul; 12(11):1400-2. PubMed ID: 9708428
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
    Wheat LJ; Farthing C; Cohen C; Pierone G; Lalezari J; Pilson RS; Siemon-Hryczyk P;
    Antivir Ther; 2002 Sep; 7(3):199-209. PubMed ID: 12487388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperlipidemia associated with the use of protease inhibitors.
    Smith JH; Martin GJ; Decker CF
    Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
    [No Abstract]   [Full Text] [Related]  

  • 5. [HIV protease inhibitors. A new drug class in antiretroviral therapy].
    Mauss S; Seidlitz B; Jablonowski H; Häussinger D
    Dtsch Med Wochenschr; 1996 Nov; 121(44):1369-74. PubMed ID: 8964223
    [No Abstract]   [Full Text] [Related]  

  • 6. New formulation of saquinavir (Fortovase) is more effective.
    Tam CW
    Fac Notes (New Orleans La); 1998; 10(2):11. PubMed ID: 11365126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saquinavir/Ritonavir: its evolution and current treatment role.
    O'Brien WA
    AIDS Read; 2006 Jan; 16(1):38-44; discussion 43. PubMed ID: 16433471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.
    Mitsuyasu RT; Skolnik PR; Cohen SR; Conway B; Gill MJ; Jensen PC; Pulvirenti JJ; Slater LN; Schooley RT; Thompson MA; Torres RA; Tsoukas CM
    AIDS; 1998 Jul; 12(11):F103-9. PubMed ID: 9708399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
    Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NDA submitted for new formulation of saquinavir.
    AIDS Patient Care STDS; 1997 Aug; 11(4):288-9. PubMed ID: 11361847
    [No Abstract]   [Full Text] [Related]  

  • 11. A patient's guide to protease inhibitors.
    Elperin A; Sax P
    AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
    [No Abstract]   [Full Text] [Related]  

  • 13. [The combination of saquinavir and ddC ensures longer survival].
    Hoof T
    Dtsch Med Wochenschr; 1996 Sep; 121(37):A30. PubMed ID: 8925721
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-HIV agents. Starting therapy with saquinavir.
    TreatmentUpdate; 2007 Jan; 19(1):8-9. PubMed ID: 17393566
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination study of Invirase and Norvir starting.
    AIDS Patient Care STDS; 1996 Jun; 10(3):187. PubMed ID: 11361633
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy.
    Moyle GJ; Sadler M; Buss N
    Clin Infect Dis; 1999 Feb; 28(2):403-4. PubMed ID: 10064262
    [No Abstract]   [Full Text] [Related]  

  • 17. [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():44. PubMed ID: 15373047
    [No Abstract]   [Full Text] [Related]  

  • 18. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.
    Nieuwkerk P; Gisolf E; Sprangers M; Danner S;
    Antivir Ther; 2001 Jun; 6(2):97-103. PubMed ID: 11491422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HIV agents. Promising results from a saquinavir study.
    TreatmentUpdate; 2007 Jan; 19(1):9-10. PubMed ID: 17390482
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.